🇮🇪Ireland
16°C Partly Cloudy · Dublin
Live Updates
--:--:-- IST
Writer Login
Latest
Clinical Trials in China / NCT07036848
Recruiting Observational

Efficacy and Safety of Surgical Treatment for Type IVa CBD

NCT07036848 · tracked via the Priya Life Science China tracker
Sponsor
Beijing Tsinghua Chang Gung Hospital
Phase
Observational
Started
2025-07-14
Last updated
2025-07-17

Condition(s) studied

Choledochal Cyst

Study summary

This study is a multicenter, bidirectional cohort study aimed at continuously enrolling patients with biliary dilatation from 25 medical centers in China. It will collect comprehensive life-cycle data from the cohort to establish a Chinese cohort for IVa biliary dilatation (BD). Based on this cohort, the study seeks to compare the perioperative risks, long-term outcomes, and quality of life of type IVa BD following surgical treatment, to establish standardized surgical treatment strategies for type IVa BD.

Eligibility

Sex
ALL
Min age
Max age
80 Years
Healthy volunteers
No
Inclusion Criteria: 1. Patients who have been diagnosed with Todani type IVa BD. 2. Patients aged between 0 and 80 years old, regardless of gender. 3. First-time receipt of surgery. Exclusion Criteria: 1. With abnormal intrapancreatic bile duct 2. Inappropriate Roux-loop length (outside the range of 40-60 cm for adults and 15-30 cm for children) 3. With non-relevant surgical interventions 4. Pathologically confirmed carcinogenesis 5. Unresolved choledocholithiasis, bile duct stenosis, and Intrahepatic bile duct stones during the procedure. 6. Unavailable follow-up information.

Primary outcome measure(s)

Trial sites (1)

FacilityCityRegionStatus
Beijing Tsinghua Changgung Hospital Beijing Beijing Municipality Recruiting

More Beijing Tsinghua Chang Gung Hospital trials in China

Other trials for the same condition

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07036848 on ClinicalTrials.gov ↗ ← All trials in China